Hepion Pharmaceuticals (NASDAQ:HEPA) Trading Up 4.2% – Should You Buy?

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) shot up 4.2% during trading on Monday . The company traded as high as $0.49 and last traded at $0.47. 74,451 shares traded hands during mid-day trading, an increase of 17% from the average session volume of 63,626 shares. The stock had previously closed at $0.45.

Hepion Pharmaceuticals Stock Down 31.4 %

The business has a fifty day moving average of $0.57 and a 200 day moving average of $0.68.

Institutional Trading of Hepion Pharmaceuticals

A hedge fund recently raised its stake in Hepion Pharmaceuticals stock. Armistice Capital LLC grew its position in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) by 32.3% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 516,000 shares of the company’s stock after purchasing an additional 126,000 shares during the period. Armistice Capital LLC owned about 9.43% of Hepion Pharmaceuticals worth $526,000 at the end of the most recent reporting period. 17.24% of the stock is currently owned by hedge funds and other institutional investors.

Hepion Pharmaceuticals Company Profile

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.